Journal
BONE MARROW TRANSPLANTATION
Volume 54, Issue 5, Pages 717-725Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41409-018-0335-x
Keywords
-
Categories
Funding
- Bologna AIL (Italian Association against Leukemia, Lymphoma and Myeloma
- Roberto and Cornelia Pallotti Legacy for Cancer Research (University of Bologna)
- REUSE with Love ONLUS, Bologna, Italy
Ask authors/readers for more resources
Umbilical Cord Blood (UCB) represents a valid option for patients with hematopoietic malignancies lacking an HLA matched donor. To overcome the limitation of the low stem cell dose of UCB, the intrabone (IB) route has been proposed. We report the results of a prospective study on a poor-prognosis cohort of 23 patients receiving intrabone single UCB transplant (Clinicaltrials.gov NCT00886522). Cumulative incidence of hematological recovery at day 90 was 82 +/- 9% (ANC > 0.5 x 10(9)/L) and 70 +/- 10% (platelet > 50 x 10(9)/L) and correlated with CD34 + cells in the graft. NRM was 20 +/- 9%. No severe aGVHD and only one extensive cGVHD occurred, with fast immune reconstitution. To test the hypothesis that the direct IB injection could affect the expression of stem cells regulatory pathways, CD34 + cells from BM aspirates at day + 10, + 20, + 30, processed in hypoxic conditions mimicking the BM-microenvironment (7%pO(2)), were studied for the expression of c-Mpl, Notch1 and CXCR4. We found that the expression of c-Mpl in CD34 + cells at day + 10 significantly correlated with hematological recovery. In conclusion, IB-UCB transplant success is associated with low incidence of GVHD and high-speed platelet recovery; intrabone route may preserve full hematopoietic stemness by direct delivery of UCB stem cells into the hypoxic HSC niche.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available